Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | REGN5837 |
Synonyms | |
Therapy Description |
REGN5837 is a bispecific antibody that targets CD28 and CD22, resulting in crosslinking of tumor cells expressing CD22 to T cells expressing CD28, which potentially leads to increased antitumor immune response (PMID: 36350988). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
REGN5837 | REGN-5837|REGN 5837 | REGN5837 is a bispecific antibody that targets CD28 and CD22, resulting in crosslinking of tumor cells expressing CD22 to T cells expressing CD28, which potentially leads to increased antitumor immune response (PMID: 36350988). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|